These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 32967009)

  • 1. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Gauthier J; Bezerra ED; Hirayama AV; Fiorenza S; Sheih A; Chou CK; Kimble EL; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Jamieson AW; Bar M; Cassaday RD; Chapuis AG; Cowan AJ; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2021 Jan; 137(3):323-335. PubMed ID: 32967009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation.
    Holland EM; Molina JC; Dede K; Moyer D; Zhou T; Yuan CM; Wang HW; Stetler-Stevenson M; Mackall C; Fry TJ; Panch S; Highfill S; Stroncek D; Little L; Lee DW; Shalabi H; Yates B; Shah N
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35534047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy.
    Xu Q; Shi Y; Xue L; An F; Xu H; Liu X; Zhu X; Sun Z; Zhai Z; Wang X
    Cell Transplant; 2023; 32():9636897231204724. PubMed ID: 37846503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
    Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
    J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
    Ji Q; Wu X; Zhang Y; Zeng L; Dong Y; Liu R; Li B; Bai Z; Hu S; Lu J; Wu S
    Eur J Haematol; 2024 Jan; 112(1):75-82. PubMed ID: 37649264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
    Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
    Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Hill JA; Li D; Hay KA; Green ML; Cherian S; Chen X; Riddell SR; Maloney DG; Boeckh M; Turtle CJ
    Blood; 2018 Jan; 131(1):121-130. PubMed ID: 29038338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
    Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
    J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
    Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
    Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
    Roddie C; Dias J; O'Reilly MA; Abbasian M; Cadinanos-Garai A; Vispute K; Bosshard-Carter L; Mitsikakou M; Mehra V; Roddy H; Hartley JA; Spanswick V; Lowe H; Popova B; Clifton-Hadley L; Wheeler G; Olejnik J; Bloor A; Irvine D; Wood L; Marzolini MAV; Domning S; Farzaneh F; Lowdell MW; Linch DC; Pule MA; Peggs KS
    J Clin Oncol; 2021 Oct; 39(30):3352-3363. PubMed ID: 34464155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Halton E; Lamanna N; Rademaker J; Sadelain M; Brentjens RJ; Park JH
    Mol Ther; 2018 Aug; 26(8):1896-1905. PubMed ID: 29910179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
    Itzhaki O; Jacoby E; Nissani A; Levi M; Nagler A; Kubi A; Brezinger K; Brayer H; Zeltzer LA; Rozenbaum M; Vernitsky H; Markel G; Toren A; Avigdor A; Schachter J; Besser MJ
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
    Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Gooley T; Li D; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Acharya UH; Cassaday RD; Chapuis AG; Dhawale TM; Hendrie PC; Kiem HP; Lynch RC; Ramos J; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(17):1876-1887. PubMed ID: 30782611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.